Trial Profile
Pyrotinib Plus Capecitabine in Patients With Brain Metastases From HER2-positive Metastatic Breast Cancer : a Single-arm, Open-label, Ahead Study
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 27 Sep 2023
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Pyrotinib (Primary)
- Indications Advanced breast cancer; Brain metastases; HER2 positive breast cancer
- Focus Therapeutic Use
- Acronyms Ahead; PERMEATE
- 22 Sep 2023 Planned End Date changed from 30 Dec 2022 to 30 Dec 2024.
- 06 Jun 2023 3-year follow-up results assessing efficacy of pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer and brain metastases presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 24 Jan 2022 Results published in the Lancet Oncology